ProfileGDS5678 / 1419485_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 50% 51% 51% 60% 49% 52% 52% 51% 49% 53% 51% 49% 51% 51% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2405550
GSM967853U87-EV human glioblastoma xenograft - Control 23.2159851
GSM967854U87-EV human glioblastoma xenograft - Control 33.2233351
GSM967855U87-EV human glioblastoma xenograft - Control 43.5264360
GSM967856U87-EV human glioblastoma xenograft - Control 53.1216849
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3759852
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3314452
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.2114451
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1401649
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2880253
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2086251
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1158549
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2416551
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2160551